(Q40821551)

English

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

scientific article published on January 1999

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

W Kreis

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

D R Budman

2

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

J Fetten

3

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

A L Gonzales

4

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

B Barile

5

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

V Vinciguerra

6

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

33-38

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Acid phosphatase: defining a role in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008354600497

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008354600497

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40821551&oldid=1908212303"